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Abstract
Background: The current study sought to assess the impact of the intraprocedural heart rhythm (sinus 
rhythm [SR] vs. atrial fibrillation [AF]) on acute procedural characteristics, durability of pulmonary 
vein isolation (PVI) and long-term clinical outcomes of cryoballoon (CB) ablation.
Methods: A total of 195 patients with symptomatic paroxysmal (n = 136) or persistent AF (n = 59) 
underwent CB-based PVI. Ablation procedures were either performed in SR (SR group; n = 147) or 
during AF (AF group; n = 48). Persistent AF was more frequent in the AF group than in the SR group 
(62% vs. 20%). All other patient baseline characteristics did not differ between the two groups.
Results: The nadir temperature during the CB applications was significantly lower in the AF 
group than in patients in the SR group (–49 [interquartile range, –44; –54]°C vs. –47 [–42; –52]°C,  
p = 0.002). Median procedure and fluoroscopy times as well as the rate of real-time recordings were not 
different between the two groups. Repeat ablation for the treatment of atrial arrhythmia recurrence was 
performed in 60 patients (SR: 44 [30%] patients; AF: 16 [33%] patients), with a trend towards a lower 
rate of pulmonary vein reconnections in the AF group (p = 0.07). There was no difference in 3-year 
arrhythmia-free survival (p = 0.8).
Conclusions: Cryoballoon-based PVI during AF results in lower nadir balloon temperatures and a 
trend towards a higher durability of PVI as compared to procedures performed in SR. The rate of real-
time PVI recordings was not affected by the intraprocedural heart rhythm. (Cardiol J)
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Cryoballoon (CB) ablation has become an es-
tablished treatment option for patients with atrial 
fibrillation (AF) [1–4]. The procedural endpoint is 
electrical isolation of the pulmonary veins (PV) [5]. 
Recent data indicate improved durability of pul-
monary vein isolation (PVI) after CB ablation than 
after radiofrequency current (RFC) ablation [6]. 
Nevertheless, the number of patients requiring 
repeat ablation because of recurrences of AF — 
mainly driven by reconnected PV — remains high 
following either approach [7]. In contrast to point-
by-point RFC ablation, the CB does not provide dif-
ferent energy levels, e.g., does not allow the use of 
higher energy settings at locations of poor tissue-
catheter contact, such as the ridge between the left 
PV and the left atrial appendage. Once the CB has 
tissue contact at the antral aspect of the targeted 
PV, cryothermal energy is delivered via the entire 
distal hemisphere of the balloon. Durable, trans-
mural lesion formation depends on the freeze cycle 
duration, and, more importantly, on the tissue con-
tact of the CB. Since the latter cannot be measured 
directly, complete occlusion of the PV, duration of 
the temperature drop and nadir CB temperature 
serve as important surrogate parameters [8]. 
Theoretically, the reduced atrial contractility dur-
ing AF might result in an enhanced stability of 
the balloon catheter and thereby, a more effective 
freeze cycle. However, to date, the impact of the 
intraprocedural rhythm (sinus rhythm [SR] vs. AF) 
during CB ablation has not yet been investigated.
The aim of the present study was to assess 
acute procedural characteristics, durability of PVI 
in patients with repeat ablation procedures and 
long-term clinical outcomes of CB ablation per-
formed during AF or in SR.
Methods
Inclusion and exclusion criteria
Patients with symptomatic paroxysmal or per-
sistent AF (as defined by 2016 ESC guidelines [5]) 
were included in the current study. Exclusion crite-
ria were prior left atrial (LA) ablation procedures, 
a LA diameter > 60 mm, severe valvular heart 
disease or contraindications to post-interventional 
oral anticoagulation. Procedures were performed at 
two centers (Asklepios Klinik St. Georg, Hamburg, 
Germany, and German Heart Institute, Berlin, 
Germany).
The current study constitutes a retrospec-
tive analysis based oninstitutional databases. The 
study was approved by the local ethics boards and 
performed in accordance with the Declaration of 
Helsinki of 2013.
Preprocedural management
Transesophageal echocardiography was per-
formed prior to PVI in all patients to rule out 
intracardiac thrombi and to assess LA diameter. 
No further pre-procedural imaging was performed.
Intraprocedural management
The intraprocedural management has been 
described in detail before [4, 9, 10]. In brief, in 
patients on vitamin K antagonists the procedure 
was performed under therapeutic internation-
al normalized ratio (INR) values of 2–3. Novel 
oral anticoagulants were stopped the day before 
the procedure and were later resumed 6 hours 
post ablation. All procedures were performed 
under deep sedation using midazolam, sufentanyl 
and propofol. One or two diagnostic catheters 
were introduced via the femoral vein and/or the 
left subclavian vein and were positioned within 
the coronary sinus and/or along the His bundle. 
A single transseptal puncture was performed via 
the femoral vein under fluoroscopic guidance, us-
ing a modified Brockenbrough technique and an 
8.5 French (F) transseptal sheath (SL1, St. Jude 
Medical Inc., St. Paul, USA). After transseptal 
puncture, heparin boluses were administered in 
30-minute intervals targeting an activated clotting 
time of ≥ 300 s. Selective angiographic visualiza-
tion by dye injections or rotational angiography 
was performed to identify the individual PV ostia.
Cryoballoon-based PVI
The 28-mm second-generation CB was utilized 
exclusively in this study. The transseptal sheath 
was exchanged over a guidewire for a 12 F steer-
able sheath (FlexCath AdvanceTM, Medtronic, Inc.), 
through which the CB was advanced into the LA. 
Guiding of the CB to the target PV was performed 
over a 20-mm inner-lumen circular mapping catheter 
(Achieve™, Medtronic, Inc.) and complete occlusion 
of the PV ostium was verified by contrast injection 
through the central lumen of the inflated CB.
Patients were treated based on a “time-to-
-isolation” guided ablation protocol, i.e., after real-
time verification of PVI, freezing was continued for 
an additional 120 s. In cases where the “time-to- 
-isolation” could not be recorded, the freeze-cycle 
duration was set at 180 s; no additional bonusfreeze 
cycle was applied after successful PVI [9]. In pa-
tients undergoing CB ablation during AF, electrical 
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cardioversion was performed at the end of the 
procedure to restore SR.
An esophageal temperature probe (Sensith-
erm, St Jude Medical, Inc.; or Circa, Circa Scien-
tific, Inc.) was inserted and positioned according 
to the individual CB position to provide esophageal 
temperature monitoring. The intraluminal esopha-
geal temperature cut-off was set at 15°C [11].
During CB ablation along the septal PV, con-
tinuous phrenic nerve (PN) pacing was performed 
using a diagnostic catheter positioned in the su-
perior vena cava (6 F, InquiryTM, St. Jude Medi-
cal, Inc.). PN capture was monitored by tactile 
feedback of diaphragmatic contraction by placing 
the operator’s hand on the patient’s abdomen. In 
addition, the continuous motor action potential 
was monitored and delivery of the refrigerant was 
stopped immediately if weakening or loss of dia-
phragmatic movement was noted or the amplitude 
of the continuous motor action potential decreased 
by 30% [12, 13].
Postprocedural care
Transthoracic echocardiography was per-
formed in all patients to rule out a pericardial ef-
fusion. All patients were treated with proton-pump 
inhibitors for 4–6 weeks. Low molecular-weight 
heparin was administered in patients on vitamin 
K antagonists and an INR < 2.0 until a therapeu-
tic INR of 2–3 was reached. Anticoagulation was 
continued for at least 3 months, and thereafter 
based on the individual CHA2DS2-VASc score. 
Previously ineffective antiarrhythmic drugs were 
continued for 3 months.
Follow-up
Following a blanking period of 3 months, pa-
tients completed outpatient clinical visits at 3, 6 
and 12 months and in 6-month intervals thereafter 
according to our institutional standard; the clinical 
visits included electrocardiograms (ECGs) and 
24 h-Holter ECGs. In patients with an implantable 
cardiac device with rhythm monitoring, regular 
device interrogations were additionally performed 
in order to detect arrhythmia recurrences. Moreo-
ver, regular telephone interviews were performed. 
In case of symptoms suggestive of recurrent ar-
rhythmia, patients were advised to contact the 
outpatient clinic and subsequent clinical visits were 
immediately initiated.
Endpoints
The primary endpoints of this investigation 
were acute procedural characteristics, i.e., nadir 
balloon temperatures, procedure durations, fluor-
oscopy times, rate of real-time PVI recordings, 
and reconnection of initially isolated PV (assessed 
in patients with repeat ablation for recurrence of 
AF). Secondary endpoints were a documented 
recurrence of atrial arrhythmia with a duration of 
> 30 s outside the 3-month blanking period and 
complications, e.g., transient ischemic attack, 
stroke, pericardial tamponade, PN paralysis (PNP), 
and severe bleeding requiring blood transfusion.
Statistical analysis
All data were evaluated retrospectively. Con-
tinuous data are described as mean and standard 
deviation (SD) if normally distributed; otherwise 
the median and interquartile range [IQR, first quar-
tile; third quartile] are reported. Categorical data 
are described with absolute and relative frequen-
cies. Based on a logistic regression model (global 
test of no regression) baseline variables were 
simultaneously compared between the two groups.
Differences in procedural data were analyzed 
with a linear mixed model. Freedom from atrial 
arrhythmia recurrence was estimated with the 
Kaplan-Meier method. Differences in recurrence-
free survival were analyzed with the log-rank test. 
All p-values were two-sided and a p-value < 0.05 
was considered statistically significant. All calcula-
tions were performed with the statistical analysis 
software R (R Core Team, 2019).
Results
Patients
A total of 195 patients with symptomatic 
paroxysmal (n = 136) or persistent AF (n = 59) 
underwent PVI with the 28-mm second-generation 
CB. Ablation procedures were either performed 
in SR (n = 147) or during AF (n = 48). Persistent 
AF was more prevalent in the AF group than in 
the SR group (62% vs. 20%). All other baseline 
patient characteristics did not differ between the 
two groups (Table 1).
Procedural characteristics
In 193/195 patients, all PV were successfully 
isolated, while in 2 patients of the SR group both 
right inferior PV and one right superior PV were 
not isolated due to the occurrence of PNP. The 
nadir temperature during the freeze cycle appli-
cations was significantly lower in patients treated 
during AF than in patients treated in SR (–49 [IQR, 
–44; –54]°C vs. –47 [–42; –52]°C, p = 0.002). Me-
dian procedure and fluoroscopy times as well as the 
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rate of time-to-isolation recordings did not differ 
between the two cohorts. Procedural parameters 
are given in Table 2.
Periprocedural complications
Procedural complications were two cardiac 
tamponades requiring pericardiocentesis, an arte-
riovenous fistula and two groin hematomas with 
conservative treatment each. PNP occurred in 
3 patients resulting in absence of PVI in two right 
inferior PV and one right superior PV as stated 
previously. In 1 patient all PV were successfully 
isolated at the time of PNP. No atrio-esophageal 
fistula, no symptomatic PV stenosis, no stroke and 
no procedure-related deaths were observed.
Repeat ablation procedures
Repeat ablation for the treatment of atrial 
arrhythmia recurrence following the index CB 
procedure was performed in 60 patients (SR group: 
44 [30%] patients; AF group: 16 [33%] patients). 
Procedures were exclusively performed with the 
use of RFC guided by 3-dimensional mapping. All 
patients showed electrical reconnection of at least 
one initially isolated PV. All PV were successfully 
re-isolated. There was a trend towards a lower rate 
of PV reconnections in the AF group without being 
statistically significant (p = 0.07). Characteristics 
of PV reconnections during repeat ablation proce-
dures are given in Table 2.
Clinical follow-up
In the SR and the AF group, 1-, 2- and 3-year 
estimated arrhythmia-free survival was 78% and 
75%, 64% and 69%, and 57% and 57%, respectively. 
The log-rank test did not indicate a significant 
difference in arrhythmia-free survival between 
the groups (p = 0.8). Recurrence-free survival is 
bshown in Figure 1.
Discussion
Main findings
According to available research, the current 
study represents the first analysis investigating 
the impact of the intraprocedural heart rhythm 
during CB-based PVI on procedural characteris-
tics and clinical outcomes. The main findings are: 
1) significant lower nadir CB temperatures in pa-
tients undergoing PVI during AF than in patients 
being treated in SR; 2) a trend towards improved 
durability of PVI performed during AF; and 3) no 
influence of the basic rhythm on procedure and fluor-
oscopy times as well as the rate of time-to-isolation 
recordings during PVI. The 3-year arrhythmia-free 
survival did not differ between the two groups.
Key factors on efficacious CB ablation 
Over the last decade, CB ablation aiming at 
PVI has become an established treatment for AF. 
During this time, several predictors of freedom 
from recurrence of AF and permanent PVI have 
been identified. As such, the time to PVI (con-
firmed by real-time recordings), the thaw time, 
and the nadir temperature of the CB impact PVI 
durability [8, 14–16]. Each of these parameters 
represents a surrogate of the balloon-tissue contact 
and energy transfer, which is still the most relevant 
aspect in creating durable, transmural cryolesions. 
The present study provides new insights into the 
impact of the intraprocedural heart rhythm on 
procedural parameters and clinical outcomes of CB 
ablation. One important result is the significantly 
lower nadir CB temperature in the AF group indi-
cating that the reduced atrial contractility during 
AF is beneficial for balloon-tissue contact and en- 
Table 1. Baseline patient characteristics.




Age [years] 63 [54;70] 66 [55;71]
Male gender 92 (63) 33 (69)
Paroxysmal AF 118 (80) 18 (38)
Persistent AF 29 (20) 30 (62)
CHA2DS2-VASc score:
0 28 (19) 8 (17)
1 37 (25) 8 (17)
2 37 (25) 14 (29)
3 32 (22) 11 (23)
4 8 (5) 5 (10)
5 5 (3) 2 (4)
BMI [kg/m2] 28 ± 5 27 ± 4
LA diameter [mm] 42 ± 5 45 ± 5
LVEF < 50% 9 (6) 3 (6)
Coronary artery disease 17 (12) 6 (12)
Diabetes mellitus 17 (12) 5 (10)
COPD 9 (6) 2 (4)
Smoker 19 (13) 5 (10)
Arterial hypertension 91 (62) 29 (60)
Values are mean ± standard deviation, median [first quartile; third 
quartile], or number (%). Presence of persistent atrial fibrillation 
differ in the two groups. No difference was revealed considering 
the remaining characteristics (test of no regression: p = 0.713).
AF — atrial fibrillation; BMI — body mass index; COPD — chronic 
obstructive pulmonary disease; LA — left atrium; LVEF — left ven-
tricular ejection fraction; SR — sinus rhythm
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Figure 1. Freedom from atrial arrhythmia recurrence after cryoballoon ablation performed in sinus rhythm (SR; orange 
curve) or during atrial fibrillation (AF; blue curve). The log-rank test revealed no significant difference in arrhythmia-
-free survival between the groups (p = 0.8).
Table 2. Procedural data.
Characteristics SR group  
(n = 147) 
AF group  
(n = 48) 
P
Total procedure time [min]  130 [110; 152] 135 [120; 145] 0.497
Fluoroscopy time [min]  18 [14; 25] 20 [16; 24] 0.364
Nadir balloon temperature [°C]:   –47 [–42; –52] –49 [–44; –54] 0.002
RSPV  –50 [–44; –53] –52 [–48; –55]
RIPV  –46 [–41; –49] –48 [–43; –54]
LSPV  –47 [–42; –52] –50 [–43; –56]
LIPV  –44 [–41; –49] –48 [–43; –52]
LCPV –55 [–47; –59] –47 [–45; –51]
Real-time PVI recording: 182 (31) 59 (30) 0.950
RSPV  48 (33) 18 (38)
RIPV 40 (28) 10 (21)
LSPV 48 (34) 16 (33)
LIPV 41 (29) 14 (29)
LCPV  5 (38) 1 (25)
PV with electrical reconnection*:   100 (57) 26 (41) 0.070
RSPV 23 (52) 8 (50)
RIPV 28 (64) 10 (62)
LSPV 23 (55) 3 (19)
LIPV 24 (57) 5 (31)
LCPV 2 (100) –
Values are median [first quartile; third quartile], or number (%). *Reconnections of the pulmonary veins were assessed in the 60 patients who 
underwent repeat pulmonary vein isolation because of recurrent atrial arrhythmia. AF — atrial fibrillation; LCPV — left common pulmonary 
vein; LIPV — left inferior pulmonary vein; LSPV — left superior pulmonary vein; PV — pulmonary vein; PVI — pulmonary vein isolation;  
RIPV — right inferior pulmonary vein; RSPV — right superior pulmonary vein; SR — sinus rhythm
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ergy transfer, respectively. The second-generation 
CB features a refrigerant injection system that 
provides homogeneous cooling of the entire distal 
hemisphere of the CB. Temperature monitoring 
of the CB is realized via a thermocouple located 
inside the balloon. Reduced atrial contractility dur-
ing AF seems to enhance adherence of the CB to 
the atrial myocardium. As a result, the surrounding 
blood flow, which results in a competing warming 
of the balloon, is reduced. This allows for lower 
nadir CB temperatures and, thereby, for more ef-
fective CB applications. Accordingly, patients in 
the AF group appear to be at a lower risk for PV 
reconnection. Interestingly, data on the impact of 
the intraprocedural heart rhythm during point-by- 
-point RFC ablation are inconsistent [17, 18]. It 
is conceivable that atrial contractility might play 
a greater role in “single-shot” CB ablation. Dur-
ing the first phase of the freeze cycle adherence 
of the balloon to the myocardium is essential for 
effective energy transfer to the tissue. The reduced 
atrial contractility during AF appears to support 
this process. Point-by-point RFC ablation is more 
complex and anatomic locations, e.g., the anterior 
or posterior aspect of the PV as well as individual 
anatomic variations, might pose a greater impact 
as compared to the relatively simple use of the CB.
Another relevant finding is that real-time 
recordings and proof of the occurrence of PVI 
is not hampered by performing CB ablation dur-
ing AF. Real-time assessment of PVI is essential 
when applying time-to-isolation guided ablation 
protocols that pave the way for shorter procedure 
times without compromising procedural efficacy 
and safety [9, 19]. Aryana et al. [8] demonstrated 
that isolation of the PV within the first 60 s of the 
freeze-cycle is associated with a high durability of 
PVI. Therefore, the time to isolation provides one 
of the most powerful predictors of effective CB 
ablation [8].
Arrhythmia free-survival
In the current study, arrhythmia-free survival 
was not different between patients undergoing 
CB-based PVI during AF or in SR. A low nadir CB 
temperature is associated with a very high likeli-
hood of durable PVI; however, our findings noted 
a significantly lower nadir CB temperature and 
a trend towards a higher durability of PVI in the 
AF group did not result in improved arrhythmia-
free survival. The underlying causes might be 
multifactorial. First, a higher number of patients 
than provided in our analysis might be needed to 
demonstrate improved freedom from AF. Second, 
the prevalence of persistent AF was markedly 
higher in the AF group, and, as the experiences of 
previous studies have shown, results of catheter 
ablation for persistent AF are less successful than 
for paroxysmal AF [20–22]. Taking this into ac-
count, the similar arrhythmia-free survival in both 
groups is a positive result for the AF group.
Noteworthy, none of the 60 patients under-
going repeat ablation of AF showed permanent 
isolation of all PV underlining the impact of recov-
ered PV conduction as one of the main drivers for 
recurrence of AF following PVI [23]. Yet, the rate 
of durable PVI was unexpected low at the time of 
repeat ablation, since previous studies reported on 
a proportion of patients with permanent isolation of 
all PV following CB ablation of 15% [6], 22% [24], 
and 53% [25]. However, even if these data were 
more convincing, durability of PVI is still not yet 
satisfactory. The implementation of the CB has led 
to greater availability of AF ablation, better repro-
ducibility of clinical outcomes [26], and improved 
lesion characteristics as compared to RFC ablation 
[27], but the high proportion of reconnected PV 
demands further efforts ensuring permanent PVI 
following the index procedure. It also needs to be 
taken into consideration that only patients with 
symptomatic AF-recurrences were included in the 
study. It can be speculated that the proportion of 
durably isolated PVs is higher in patients without 
AF recurrences.
Limitations of the study
The current study is an observational, non-
-randomized analysis. The mode of the follow-
up might have resulted in an overestimation of 
freedom from atrial arrhythmia recurrences. 
A sufficiently powered randomized comparison is 
mandatory before final conclusions can be drawn.
Conclusions
In this observational study, the performance of 
CB-based PVI during AF resulted in lower nadir CB 
temperatures and a trend towards higher durability 
of PVI when compared to procedures performed 
in SR. The rate of real-time PVI recording was 
not affected by the intraprocedural rhythm. In ac-
cordance to the present findings, in CB ablation, 
electrical cardioversion of AF should be performed 
once PVI has been obtained.
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